Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/inmagene-exercises-option-to-obtain-exclusive-worldwide-license-for-img-007-and-img-004-from-hutchmed-302051787.html
https://www.prnewswire.com/news-releases/inmagene-doses-first-patient-in-phase-2a-trial-of-img-007-an-anti-ox40-monoclonal-antibody-with-an-extended-half-life-for-the-treatment-of-alopecia-areata-301956087.html
https://www.prnewswire.com/news-releases/inmagene-announces-formation-of-celexor-bio-based-on-its-anti-ilt7-mab-with-enhanced-pdc-depletion-function-301934416.html
https://www.prnewswire.com/news-releases/inmagenes-anti-ox40-mab-demonstrated-an-extended-half-life-and-a-favorable-safety-profile-in-a-phase-i-study-301904386.html
https://www.prnewswire.com/news-releases/inmagenes-ox40-mab-with-an-extended-half-life-and-silenced-adcc-enters-poc-study-in-atopic-dermatitis-301901200.html
https://www.clinicaltrialsarena.com/news/inmagene-topline-data-img-004/
https://www.prnewswire.com/news-releases/inmagene-receives-ind-clearance-for-img-008-a-long-acting-il-36r-mab-301739146.html
https://www.prnewswire.com/news-releases/inmagene-and-hutchmed-announce-first-participants-in-global-phase-i-trial-of-img-007-301581096.html
https://www.prnewswire.com/news-releases/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-data-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-presented-during-2022-european-alliance-of-associations-for-rheumatology-congress-301560613.html
https://www.prnewswire.com/news-releases/inmagene-receives-fda-ind-clearance-for-a-third-generation-btk-inhibitor-targeting-immunological-diseases-301547448.html